

Index

a

- Ab initio* quantum chemical methods
185–186
- accelerated molecular dynamics (aMD)
32, 49, 52
- ACE model 94
- adaptive biasing force (ABF) 52, 252,
253, 268, 271
- adiabatic bias metadynamics 238–241
- adiabatic bias molecular dynamics
(ABMD) 238
- adio-ligand-binding assay 254
- Alchemical methods 15, 16, 50–51, 88
- Aliskiren 182
- allosteric effect 118, 282–284, 287, 288
- allosteric two-state model (ATSM)
283, 287
- allostery
 - behavior and application 288–289
 - chaperones 291–293
 - classic view of 283
 - defined 281
 - ensemble allosteric model 287–288
 - GPCRs 294–296
 - Protein kinases 293–294
 - structural and dynamic approaches
289–291
 - thermodynamics to protein structure
and dynamics 285–287
 - thermodynamic two-state model of
283–285
- Amprenavir 180
- amyloid beta (A β) 34
- anaplastic lymphoma kinase (ALK)
174, 183, 184
- angiotensin-converting enzyme (ACE)
94, 167, 169
- angiotensin II 169, 170, 238
- angiotensin receptor II 170
- angle bending 250
- anisotropic network model (ANM)
91–93
- antimicrobial peptides 34
- antiparallel packing (APP) 34, 304
- antiparallel sheets (APS) 304–306,
308, 313, 317
- Arrhenius-like formula 59
- asparagine (N) and glutamine(Q)
polypeptides
 - aggregate formation 318–319
 - initial structures 313–314
 - N-rich oligomers 315–316
 - polyQ β -hairpins 314–315
 - polyQ β structures 316–318
- atomic solvation factor (SF) 239
- atomistic representations 206, 226
- average path length 109

b

- backbone-oxygen atoms 257
- Bayes factor 77
- Bayesian agglomerative clustering
engine (BACE) algorithm 77
- Bennett acceptance ratio 16
- benzamidine-trypsin system 189
- β -arrestin-biased ligands 211
- β -lactamase enzyme inhibitor 179
- betrixaban 178
- bias exchange metadynamics 13, 35,
264

- biasing potential 52, 252
- BILN-2061 177, 178
- binding free energy 12, 14–17, 35–37, 55, 56, 176, 187, 189, 260, 286
- binding kinetics 6, 20, 57–59, 190, 211, 226, 234
- binding pocket 37, 55, 75, 77, 118, 169, 173, 176, 184, 185, 190, 210, 211, 214, 227, 232, 236, 238, 239
- biochemical assays 331
- biochemical pathway regulation 281
- Biomolecular and Organic Simulation System (BOSS) 88, 89
- biomolecular recognition 29, 30
- biomolecular simulations
 - accuracy of 8–10
 - binding free energy 14–16
 - design of 4–6
 - equilibrium design 5
 - evaluative design 4
 - free energy estimates 16–20
 - refinement design 5
 - sampling 10–14
 - trajectory clustering 6–8
- biomolecular systems 10, 11, 17, 141, 166, 250
- Boltzmann constant 7, 49, 53, 69, 235, 251, 262, 286
- Boltzmann distribution 54, 69–71, 87, 137, 236
- Brigatinib 183, 184
- C**
- Ca²⁺ accumulating region (CAR) 269
- calcium-saturated calmodulin (CaM) 287
- Captopril 167, 169
- carbonic anhydrase (CA) II 185
- carboxypeptidase A 167
- casein kinase 2 (CK2) 329–331
- Cdc34
 - acidic loop of 332–333
 - catalytic activity 334
 - different strategies to target 333–334
 - heterogeneous conformational ensemble 329–330
 - leucine 329
 - overexpression and increased ubiquitination 326
 - from phenotype to structure 331–332
 - protein sequence and structure 328–329
 - structure and dynamics 326
- Cdc34-like proteins 330
- cell cycle progression 325, 328, 333
- centrality measures 109–114, 116, 118
- chaperones 119, 291–293
- Chapman–Kolmogorov test 73, 210
- CHARMM-GUI 9
- chemoinformaticians 20
- Chou–Fasman method 182, 184
- CK2 kinase 330
- classical metadynamics 13, 19
- clustering coefficient 109
- coarse-grained (CG) models of proteins 106
- coarse-grained representations 121, 206
- coarse grained elastic network models (CG ENMs) 122–125, 130, 136, 137, 139, 141
- collective variables (CVs) 6–8, 32, 51, 52, 56, 59, 240, 250, 252
- computational alanine scanning (CAS) 34
- computer-aided drug discovery (CADD) 30, 45, 47, 50, 59, 165, 166, 190, 296
- conformational flooding 32, 52
- continuous tempering MD (CTMD) 48
- corticotropin-releasing factor 239
- corticotropin-releasing factor receptor 1 (CRF₁R) 239
- Coulomb potential 132, 250
- Coulomb's law 179
- Crizotinib 174, 184
- cryo-electron microscopy 173, 248

- cyclic adenosine monophosphate (cAMP) 282, 286, 287, 291
- cyclin-dependent kinase 5 (CDK5) 56, 190
- cyclin-dependent kinase (CDK) inhibitor 333
- cyclophilin A (CypA) 189
- cyclosporin A 78, 79
- d**
- (*S,S,S*)-decahydro-isoquinoline-3-carbonyl (DIQ) 168
- degree of complexity 30
- degrees of freedom 12, 13, 30, 32, 54, 120, 137, 169, 175, 206, 240, 252, 287, 318, 319
- delta opioid receptor (DOR) 190
- de novo* drug design 175, 180–181
- dentatorubral-pallidolusian atrophy (DRPLA) 301
- diarylpyrimidine (DAPY) compound 176
- digraphs 107
- dimethylphosphine oxine (DMPO) 183, 184
- directed graphs 107
- divalent cation sensor (DCS) 265, 266
- docking algorithms 30, 179, 254
- dominant eigenspace 70–72
- dopamine receptor D_2 (D_2R) 212
- dopamine receptor D_3 (D_3R) 211
- Dorzolamide 185–186
- double decoupling method 36
- drug (un)binding 209
- drug design, Markov state models 67
- drug design process 165, 180
- drug development
- classical approaches of 281
 - targets and strategies for 281
- drug discovery
- allostery for 289
 - exploiting allostery in 288–289
 - partnerships 281
 - pipeline 57
 - target-centric 281
- drug discovery process
- Captopril 167
 - early days 166–167
 - ligand-based methods 169–173
 - pharmacophore modeling 171–172
 - quantitative structure-activity relationships (QSAR) 172–173
 - Ritonavir 168
 - Saquinavir 167–168
 - structure-based methods 173–185
 - use of computer-aided methods in 168–186
- drug resistance mechanisms 281
- e**
- E2 catalysis 327
- E2 enzymes 325
- families of 327–328
 - phosphorylation 332
- elastic network models (ENMs) 106, 124
- general principles 123–124
 - residue interaction networks (RINs) 124–127
- electrostatic ENM (eENM) 137, 138, 253, 308
- end-point methods 36, 47, 50–51
- energy minimization 89, 92, 94, 175, 179
- enfuvirtide 184
- enhanced sampling method 38, 46, 47, 57, 59, 88, 180, 294
- ensemble allostery model 287–288
- enzyme characterization 96–97
- equilibrium constant 17, 18, 235, 284
- E3 recognition site 330–331
- Eyring's equation 235
- f**
- fibroblast growth factor receptor (FGFR) 13, 190
- flexible receptor molecular docking 179
- fluorescence microscopy technique 20

- flying Gaussian method, 11force field
8–10, 16, 20, 21, 31, 32, 37–39,
45–48, 55, 59, 87, 88, 94, 121,
166, 175–180, 182, 188, 206,
230–232, 241, 250, 251, 263, 299,
303, 304
- free energy
ABF 252–253
barrier 286
estimates 16–20
metadynamics 252
methods 264–270
perturbation 88, 251, 257–260
umbrella sampling 251–252,
257–260
of zipper formation 318
free energy perturbation (FEP) 16, 32,
51, 81, 88, 187, 230, 251, 257
FEP thermodynamic cycle 187,
188
free-energy simulation methods 32
free energy surface (FES) 7, 8, 11–15,
19, 20, 31, 48, 52, 53, 240, 253
FTMAP algorithm 296
funnel metadynamics 15
- g**
- gamma aminobutyric acid (GABA)
receptors 262
Gartner hype cycle 4
gastrointestinal stromal tumor (GIST)
183
Gaussian accelerated MD (GaMD) 52
Gaussian function 132, 252
Gaussian network models 294
General Amber Force Field (GAFF) 9
Generic GPCR Residue Numbering
227
genetic algorithm for graph similarity
(GAGS) search 134
genetic algorithms 175
Gibbs' free energy 235
glucokinase activation 282
GPCR ligand design
adiabatic bias metadynamics
238–240
application of MD simulations 226
ligand binding free energy 230–233
ligand binding kinetics 233–240
role of water 226–230
supervised molecular dynamics
(SuMD) 235–237
WaterMap and WaterFlap 228–230
G protein-coupled receptors (GPCRs)
96, 118, 294, 296
activation or inactivation 208
drug design 210–214
modulation 213
plasticity of 207
sampling problem and simulation
timescales 208–209
sharing dynamic data on 216
simplified energy landscape of 208
simulation data 209–210
subtypes 212
timescales 214
graphical processing units (GPU) 11,
30, 31, 67, 166, 180, 215, 232,
237
graphs, of protein structures 107
Grazoprevir 177, 178
GRID 181, 227–230, 241
Gromos clustering algorithm 7
- h**
- hepatitis C virus (HCV) 177
high-throughput screening (HTS) 165,
183, 295
Hilbert space 70
HOLE program 257
homology modeling 33, 169, 175, 182,
183, 248–249, 254, 264, 269, 271,
331
Hsp90 34, 59, 119, 291–293
C-terminal domain (CTD) 292, 330,
335
C-terminal targeted drugs 292
human immunodeficiency virus-1
protease (HIV-1 PR) 35, 96,
120, 167, 175, 180, 290
Huntington's disease (HD) 301

- hydrogen bond 10, 34, 78, 121, 125, 167, 171–173, 176, 180, 183, 227, 230, 302, 304, 306, 308, 315, 318, 334
- hydrophobic gate 264–270
- hydroxyethylamine compounds 168
- 5-hydroxytryptamine (5-HT) 171, 211, 266
- 5-hydroxytryptamine receptor 2A (5-HT_{2A}) 211
- 5-hydroxytryptamine receptor 3 (5-HT₃) receptor 266
- i**
- ICM Docking module 179
- indinavir 175
- INFOMap algorithm 128, 139, 140
- instantaneous force 252, 253
- ion channel
- calculation of free energy 251–253
 - drug discovery studies 247
 - force field 250
 - free energy perturbation and umbrella sampling 257–260
 - homology modeling 248–249
 - ion conductance calculations 260–263
 - malfunctioning of 247
 - melatonin receptors 254
 - molecular dynamics simulations 249–250
 - properties of 253–264
 - Trk1p 253–254
 - TRP channels 263–264
 - voltage-gated sodium channels (Nav) 254–256
- ion conductance calculations
- low conductance GLIC channel 261–263
 - VDACs 261–262
- isothermal titration calorimetry (ITC) 33, 187
- j**
- Jacobian matrix 253
- k**
- protein kinases 118, 293, 294
- kinetics rate constants 234, 235
- knock-on mechanism 258
- l**
- λ windows 187, 233
- Lennard–Jones potentials 3, 51, 179, 250
- ligand-based methods 169–173
- ligand binding free energy 230–233
- ligand binding kinetics 233–240
- ligand perturbation 91, 92
- ligand–protein complex 36, 176, 229, 235
- ligand–receptor complex 29, 237
- ligand–receptor interactions 211, 229
- local-elevation method 32
- lock-and-key model 29, 67
- long-lived conformations 75, 77–79, 81
- losartan 169–171
- low conductance GLIC channel 261–263
- m**
- mapping protein ligand 90, 94–96
- Markov chain model 8, 20
- Markov chain Monte Carlo (MCMC) 3, 48, 87
- Markovian dynamics 70, 71
- Markov state models (MSM) 57, 72–75, 210
- dominant eigenspace 70–72
 - long-lived conformations 77–79
 - MD simulations 68
 - microstates 75–77
 - molecular ensemble 69
 - propagator 69–70
 - transition paths 79
- MC for proteins (MCPRO) 88, 89
- MC-minimization technique 89
- MC software 90
- MDM2 76
- MD simulations
- advantage of 179
 - of cAMP-free (apo) 291

- MD simulations (*contd.*)
- Markov state models 68
 - multi-replicate approach 330
 - technique 68
- mean first passage time (MFPT) 80, 81
- melatonin receptors 254, 270
- metadynamics (MetaD) 12, 52–57
- accuracy of 12
 - application of 12
 - biased simulation 12
 - potential 53
- microstates, drug design 75–77
- migration inhibitory factor (MIF) 232
- MK-927 185, 186
- muscarinic (M_3) receptor 238
- molecular docking-virtual screening 175–178
- molecular dynamics (MD)
- alchemical methods 50–51
 - binding kinetics 57–59
 - collective variables (CVs)-based methods 51–52
 - vs. docking 30–31
 - end-point methods 50
 - limits of 46–47
 - metadynamics (MetaD) 52–57
 - methods 225
 - multiple replica methods 48–50
 - non-Markovian 32
 - protein-ligand binding 36–38
 - protein-peptide binding 34–36
 - protein-protein binding 32–34
 - simulations 6, 30, 45, 179–180
 - application of 210–214
 - GPCR functionality 205
 - ion channel 249–250
 - robustness and stability 249
 - timescales 214
 - state of art 31–32
 - tempering methods 47–48
 - tools 234
- metadynamics
- bias exchange 13, 35, 264
 - classical 13, 19
 - funnel 15
- molecular ensemble 69
- molecular graphs 105, 141, 173
- molecular mechanics (MM) 8, 9, 16, 35, 36, 50, 81, 88, 94–97, 172, 176, 177, 229, 238
- molecular mechanics/generalized born surface area (MM/GBSA) 16, 50
- molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) 16, 36, 50, 51, 81
- molecular modeling techniques 165
- Monte Carlo (MC)
- method 3, 11, 18
 - simulations 179, 230
 - techniques
 - free energy calculations 88
 - and MD combinations 89–90
 - optimization 88–89
 - sampling procedure 91–92
- Monte Carlo *de novo* ligand generator (MCDNLG) 181
- MSMs. *See* Markov state models (MSMs)
- multi-grained (MG) models 131
- multiple replica methods 14, 48–50
- MWC model 283
- n**
- negative allosteric modulators (NAMs) 239
- Nelfinavir 180–181
- nerve signal transmission 247
- network diameter 109, 113
- network sciences
- development of 106
 - modularization techniques 107
 - rise of 105–107
- Newton's equations of motion 87, 250
- Newton's laws of motion 31, 179
- nicotinic acetylcholine receptors (nAChRs) 262, 266
- NMR spectroscopy 29, 36, 117, 169, 173, 286
- nonequilibrium candidate Monte Carlo (NCCMC) 89
- non-nucleoside reverse-transcriptase inhibitor (NNRTI) 176

- nonpeptide compound 169
- non-small cell lung cancer (NSCLC)
174, 183, 184
- norfloxacin 173
- nuclear magnetic resonance (NMR)
17, 29, 33, 79, 117, 169, 248, 286,
315
- nucleation-growth polymerization 301
- o**
- optimization algorithm 48
- p**
- parallel artificial membrane
permeability assays (PAMPA)
12
- parallel packing (PP) 304
- parallel sheets (PS) 304, 313
- parallel tempering (PT) 14, 31, 48, 49,
189
- partial-path transition interface
sampling (PPTIS) 58
- path-based collective variables
(PathCVs) 56
- peptides and proteins
design of multiscale ENMs 135–140
graph reduction of three-dimensional
molecular fields of 132–135
- periodic boundary conditions (PBC) 8,
237, 260
- Perron-cluster cluster analysis+
(PCCA+) 77
- pharmacokinetics (PK) 172, 178, 183,
184, 233, 236, 239
- pharmacophore modeling 20, 171, 172
- Philadelphia chromosome-positive
chronic myeloid leukemia (Ph+
CML) 175
- phosphoglycerate dehydrogenase
(PGDH) 285
- Planck's constant 235
- platelet-derived growth factor receptors
(PDGFRs) 183
- Poisson–Boltzmann surface area (PBSA)
81, 187
- polar zipper mechanism 308
- polar zipper model 308
- polyglutamine protofibrils and
aggregates
monomeric Q40 protofibrils 308
oligomeric Q8 structures 303–306
time evolution, steric zippers and
crystal structures 306–308
- poly(ADP-ribose) polymerase (PARP)
184
- population shift 29, 285
- potential energy 49
function 250
surface 71
- potential of mean force (PMF) 189,
252, 256, 262, 264
- principal component analysis (PCA) 7,
34, 91, 209
- Prion diseases 302
- probability distribution 7, 54, 72, 74,
137
- Protein Data Bank (PDB) 33, 116, 126,
249, 267, 285
- protein-drug interactions 96
- protein dynamics, networks
coarse-graining 120–122
ENMs 123–124
molecular simulations 117–119
RINs design 124–127
software 119–120
- protein energy landscape exploration
(PELE) method 89
coordinate exploration 93–94
energy function 94
enzyme characterization 96–97
ligand perturbation 91
mapping protein ligand and
biomedical studies 94–96
MC sampling procedure 91–92
minimization 93
process flow in 92
receptor perturbation 91–92
side chain readjustment 93
web server 95
- protein folding 7, 9, 253
- protein kinases 118, 293, 294
A (PKA) 35, 79, 291

- protein kinases (*contd.*)
 casein kinase 2 (CK2) 329–331
 cyclin-dependent kinase 5 (CDK5)
 56, 190
 receptor tyrosine (RTK) 174, 182,
 183
- protein–ligand binding 15, 30, 32, 33,
 36–38, 87, 175, 227, 230
- protein–ligand complex 4, 6, 10, 17,
 33, 87, 175, 176, 227, 238
- protein–ligand docking 4, 20
- protein–ligand interaction 12, 15, 30,
 38, 90, 97, 174, 235, 238
- protein–ligand unbinding 87
- protein–peptide binding 34–36
- protein–peptide complex 34, 35
- protein–peptide recognition 34
- protein–protein binding 32–34, 129
- protein–protein complexes 33, 34
- protein–protein docking 33, 34, 107
- protein–protein interactions (PPIs) 32,
 77, 111, 113, 170, 226, 325, 326,
 333, 334
- protein–protein interfaces 33, 34
- protein–protein system 33
- protein stability 109, 129
- protein structure network 107, 331
- protein structure prediction 89,
 181–184
- protein structures, networks
 centrality measures 110–114
 software 114–117
 topological features and analysis
 107–110
- protofibrils 301, 303–310, 319, 320
- q**
- quantitative structure-activity
 relationships (QSAR) 172–173,
 190, 292
- quantum mechanics and molecular
 mechanics (QM/MM) 8, 96, 97
- r**
- raltegravir 46, 290
- Really Interesting New Gene (RING)
 117, 328, 333
- receptor perturbation 91–92
- receptor tyrosine kinase (RTK) 174,
 182, 183
- reduced point charge models (RPCMs)
 121, 137
- replica-exchange accelerated molecular
 dynamics (REXAMD) 49
- replica exchange algorithm 49
- replica-exchange molecular dynamics
 (REMD) 31, 32, 49
- replica exchange thermodynamic
 integration (RETI) 89
- replica exchange with solute tempering
 (REST) 49, 89, 190, 232
- residue interaction networks (RINs)
 107, 124–130
 centrality measures of 118
 design of mesoscale protein models
 130–131
 modularization of 128–130
- reweighting formula 12, 19
- rilpivirine 176, 177
- Ritonavir 168
- root mean square distance (RMSD)
 5–7, 56, 77, 93, 95, 134, 209
- Rucaparib 184–185
- S**
- Saccharomyces cerevisiae* Cdc34
 (ScCdc34) 328, 331, 334
 acidic loop 328
 casein kinase 2 (CK2) 331
- sampling water interfaces through
 scaled Hamiltonians (SWISH)
 50
- Saquinavir 167–168
- selectivity filter 253, 255–260, 264,
 268, 269, 271
- side chain readjustment 93
- simulated annealing (SA) 31, 48, 88,
 177, 181
- simulated tempering (ST) 48
- single-molecule fluorescence detection
 29
- single nucleotide polymorphisms
 (SNPs) 212
- six spinocerebellar ataxias (SCA) 301

- solvent accessible surface area (SASA) 91
- spinal-bulbarmuscular atrophy (SBMA) 301
- standard deviation 16, 18, 20, 59
- standard error 16, 18
- steered molecular dynamics (SMD) 11, 267
- stromal interaction molecules (STIMs) 267, 268
- structure-activity relationships (SAR) 168, 229, 234, 235
- structure-based drug design (SBDD) 3, 37, 67, 75, 82, 165, 169, 174, 175, 180, 182, 208, 230, 235, 248, 271, 295
- structure-based methods 173, 185
- Brigatinib 183–184
- Crizotinib 174–175
- de novo* drug design 180
- enfuvirtide 184
- flexible receptor molecular docking 179
- Grazoprevir 177–178
- molecular docking–virtual screening 175–176
- molecular dynamics simulations 179–180
- Nelfinavir 180–181
- protein structure prediction 181–183
- Rucaparib 184–185
- structure-kinetics relationships (SKR) 234
- Sunitinib 182, 183
- supervised molecular dynamics (SuMD) 235–238, 241
- surface generalized born (SGB) model 94
- t**
- teleportation 128
- tempering methods 47–48
- thermodynamic ATSM 287
- thermodynamic cycle 18, 187, 231, 284
- thermodynamic integration 16, 32, 51, 88, 89, 187
- thermodynamic two-state model 283–285
- 3D Quantitative Structure Activity Relationship (3D-QSAR) 292
- time-dependent independent component analysis (tICA) 81, 209
- time-homogeneous dynamics 69
- time-lagged independent component analysis (tICA) 81
- tirofiban 170, 171
- TmCorA protein 265
- total dipole (TD) 304
- trajectory clustering 6–8
- transduction mechanism 109, 292
- transient receptor potential (TRP) channels 263–264
- transient receptor potential vanilloid type 1 (TRPV1) 264
- transition paths 52, 56–59, 79–81, 291
- transition path sampling (TPS) 57–59
- transition state partial-path transition interface sampling (TS-PPTIS) 58
- transition state theory 32, 58, 235
- transmembrane (TM) helices 255–257
- potential 261
- protein 184
- 7-transmembrane (7TM) receptors 294
- trinucleotide repeat expansion diseases (TREDs) 319
- Trk1p 253–254
- truncated Newton algorithm 92, 93
- tyrosine kinase (Syk) inhibitors 189
- Tyr-Tyr interactions 315
- u**
- ubiquitination assay 334
- ubiquitin conjugating (UBC) 327, 329–332, 335

- ultra-CG models 122
 - umbrella sampling 11, 12, 19, 32, 52, 189, 190, 251–252, 257–260, 262, 266, 267, 271
 - Food and Drug Administration (FDA) 166, 290
- V**
- Vaborbactam 179
 - vacancy diffusion mechanism 258
 - valsartan 170, 171
 - van der Waals interaction 250, 303, 315
 - vascular endothelial growth factor receptor (VEGFR) 182
 - venous thromboembolism (VTE) 178
 - virtual-library screening (VS) 30
 - visual molecular dynamics (VMD) 10
 - voltage-dependent anion channels (VDACs) 261, 262
 - voltage-gated sodium channels (Nav) 254–256
 - Voronoi cells 126
- W**
- Wang–Landau sampling 32, 89
 - WaterFlap 228–230, 241
 - WaterMap 228–230
 - water network 30, 227, 230, 241, 242
 - weighted histogram analysis method (WHAM) 12, 19, 20, 32, 52, 252
 - weighted histogram techniques 32, 189
 - well-tempered metadynamics 13, 19, 252
- X**
- X-ray crystallography 29, 33, 36, 117, 169, 173, 238, 262, 286, 290
 - X-ray diffraction patterns 303, 308, 315
- Z**
- Zanamivir 181
 - zero dipole (ZD) 304, 305
 - zolmitriptan 171, 172
 - Zwanzig relationship 51